We are pleased to have met Matteo and the INTA's team. These days we could appreciate the commitment, competence, and passion of the team to bring their research results on the market. We strongly believe that this technology will have a deep and durable impact worldwide.

A crystal-clear need, relevant feedbacks from opinion-leaders of the clinical environments and also from the market. Besides, a wide gamut of potential applications of the technology with tailored artificial intelligence solutions for clinics, commitment, and competence of the team, excellence of the academic environment, these are just a few of the reasons behind our investment.

A textbook example, rarely seen in Italy: from a research project for quantum-cryptography founded by the EU, novel biomedical technology has been developed. Thanks to the multidisciplinary environment which permeates the NEST Laboratory, excellent researchers from “Scuola Normale Superiore” and CNR-NANO could give birth to this technology working side-by-side. This novel architecture for biomedical diagnostics has massive potential. We strongly believe that this will be just the beginning of a success story!

The commitment of CNR is clear to bring value and new professional horizons for CNR technologies and researchers. This has been made possible thanks to key collaborations with important institutions as the "Scuola Normale Superiore”. The investment of Eureka! Venture and A11 Venture is the first fundamental result that stems from the determination and quality of the INTA’s team. It will create value and new perspectives for this amazing technology